Skip to content
Vivo logo
← All articles

NAD for Energy: 23 Studies, but No Consistent Functional Gains

NAD for Energy: 23 Studies, but No Consistent Functional Gains

Steady biomarker rise beside uneven functional outcomes

NAD is essential for cells to make ATP, but current human trials show mixed evidence that NAD therapies reliably relieve fatigue. A 2024 trial in long-COVID patients found no significant fatigue improvement from nicotinamide riboside, while a 2022 review of 23 studies found biomarker increases without consistent functional gains. Anyone considering NAD-based treatment should weigh this evidence alongside how the product is sourced and supervised.

TL;DR:

  • A 2024 trial involving 58 people with long COVID found no significant fatigue benefit from nicotinamide riboside compared with placebo (p=0.59).
  • A 2022 review of 23 studies found that precursors reliably raised blood NAD+ biomarkers, but most trials showed no significant gains in performance or frailty.
  • The small RiaGev pilot reported a 27% rise in NADP+ and lower fatigue scores after seven days, but its short duration limits confidence.
  • Before choosing injectable or nasal treatment, verify the pharmacy is licensed, documents sterility and endotoxin testing, and supplies products under provider supervision.
Vivo Clinicvivoclinic.orgExplore Supervised NAD+ OptionsVivo Clinic offers provider-supervised NAD+ therapies, including nasal sprays, with precision-compounded treatments prepared by licensed U.S. pharmacies.Explore NAD+ treatment

Table of Contents

What NAD is and how NAD+ and NADH support cellular energy

NAD, or nicotinamide adenine dinucleotide, is a coenzyme present in every cell, where it shuttles electrons between chemical reactions. It exists in two interconvertible forms: NAD+, the oxidized form that accepts electrons, and NADH, the reduced form that carries them. This back-and-forth, known as redox cycling, is fundamental to how cells extract usable energy from food.

NAD+ and NADH participate in three connected stages of energy metabolism. Glycolysis breaks down glucose in the cytosol and generates NADH as a byproduct. The TCA cycle, which runs inside mitochondria, produces additional NADH from the breakdown products of carbohydrates, fats, and proteins. The electron transport chain then uses that NADH to generate ATP, the molecule cells actually spend as energy currency. According to a mechanistic review of NAD+ metabolism, this redox cycling underlies energy metabolism across glycolysis, the TCA cycle, and mitochondrial ATP production.

One detail often missed in consumer discussions is compartmentalization. NAD pools inside mitochondria and in the surrounding cytosol are regulated somewhat separately, and they do not always rise or fall together.

  • NAD+ accepts electrons during glycolysis and the TCA cycle, then becomes NADH.
  • NADH delivers those electrons to the mitochondrial electron transport chain, where ATP is produced.
  • Mitochondrial and cytosolic NAD pools are regulated separately, which affects how an oral or injected precursor actually reaches the tissue where it matters.

That compartmentalization matters later, because a supplement or therapy that raises NAD in the bloodstream does not automatically raise it where mitochondria do their work.

Why biochemical support doesn’t always translate to feeling more energetic

Cellular energy metabolism and the subjective experience of fatigue are related, but they are not the same measurement. A trial can show a clear rise in a biomarker, such as blood NAD+ or NADP+, while participants report no change in how tired they feel. This gap between biomarker and subjective endpoint is one of the most consistent patterns in NAD research, and it explains much of the confusion around claims of an energy boost.

Part of the gap comes from how fatigue itself is measured. Subjective fatigue scales are sensitive to placebo response, daily variation, and individual expectation, so a small sample size can produce a result that looks meaningful but does not hold up in a larger trial. Response also varies by individual: some people metabolize precursors differently, and baseline NAD status at the start of a study affects how much room there is for measurable change.

A 2022 pilot trial of RiaGev (a combination of nicotinamide and D-ribose) found a 27% increase in NADP+ compared with placebo, alongside a statistically significant reduction in fatigue scores over seven days, according to the RiaGev pilot trial and systematic review. That short-term, small-scale result stands in contrast to larger or longer trials, where functional and subjective improvements have mostly failed to reach significance.

Where benefits have shown up at all, they tend to be domain-specific rather than a general sense of more energy. Some trials report modest gains in endurance capacity or specific cognitive tests. Others, including trials measuring perceived fatigue directly, have found no meaningful difference from placebo. This pattern, improvement in a narrow physiological measure without a matching change in how someone feels day to day, appears often enough in the literature that it should temper expectations rather than dismiss the biology entirely.

Why biochemical support doesn't always translate to feeling more energetic — overview diagram

What the human clinical evidence shows for NAD and fatigue

The clearest way to understand where NAD research stands is to look at what different types of studies actually measured, not just whether they were “positive” or “negative.” Biomarker studies consistently show that NAD+ precursors can raise blood NAD+ levels. Functional studies, which measure things like physical performance, frailty, or fatigue scores, show a much less consistent picture.

The 2024 nicotinamide riboside trial in long-COVID patients is a useful anchor point. With 58 participants, it found no significant difference in fatigue severity between the treatment group and placebo, with a p-value of 0.59, a result far from statistical significance. This was a population selected specifically because fatigue was a primary complaint, which makes the null result notable rather than incidental.

The 2022 systematic review of 23 studies reached a broadly similar conclusion at a larger scale: NAD+ precursors reliably raised blood NAD+ biomarkers across the reviewed studies, but most trials reported neutral, non-significant findings for physical performance or frailty measures. The same review did highlight exceptions, including the RiaGev pilot described above, which suggests that formulation, dosing, and study duration all influence outcomes.

Study Population Biomarker result Functional/fatigue result
2024 nicotinamide riboside trial 58 long-COVID patients Not the primary focus No significant fatigue improvement (p=0.59)
2022 systematic review, 23 studies Mixed adult populations NAD+ biomarkers increased Mostly neutral for performance and frailty
RiaGev pilot trial Healthy middle-aged adults NADP+ increased 27% Reduced fatigue, CIS score

A few patterns explain why the field looks this inconsistent. Sample sizes are often small, which limits statistical power to detect modest effects. Dosing and treatment duration vary widely between studies, so a seven-day pilot and a multi-month trial are not really answering the same question. Endpoints differ too: some trials track blood NAD+, others track NADP+ or intracellular measures, and a few rely entirely on self-reported fatigue questionnaires. Because compounded and over-the-counter products are not standardized the way an FDA-approved drug would be, outcomes can also depend heavily on the specific formulation and provider involved.

For a reader deciding whether to try an NAD-based approach, a few practical takeaways follow from this evidence:

  • Expect biomarker change to be more likely than a dramatic shift in how you feel day to day.
  • Treat any single small trial, positive or negative, as preliminary rather than conclusive.
  • Pay attention to how a product or therapy is sourced, since formulation and provider quality affect outcomes as much as the ingredient itself.

How people try to raise NAD: oral, IV, nasal, and topical options

People pursuing higher NAD levels generally choose from four delivery categories, each with distinct tradeoffs in evidence, convenience, and oversight.

  1. Oral precursors (NR, NMN, NAM): nicotinamide riboside, nicotinamide mononucleotide, and nicotinamide itself are the most studied oral forms. They reliably raise circulating NAD+ biomarkers in many trials, though some forms degrade quickly in digestion, and a 2026 study of a specialized oral formulation found a 53% increase in intracellular NAD in blood cells without any corresponding rise in plasma NAD, a reminder that the biomarker you measure can change the story you tell about effectiveness.
  2. IV and injectable NAD+: intravenous and injectable approaches can deliver NAD+ directly into circulation, bypassing digestion. No standardized, FDA-approved IV NAD+ formulation exists, so efficacy and safety are described as batch-dependent, varying with the specific compounding pharmacy and protocol used, according to reporting on NAD injection recalls.
  3. Prescription compounded nasal sprays: compounded nasal sprays deliver NAD+ through the nasal mucosa under a provider’s prescription, differing from off-the-shelf supplements in that they are prepared by a licensed compounding pharmacy rather than sold as a mass-market product. Vivo Clinic’s NAD+ nasal spray is one example of this prescription format.
  4. Topical creams: topical NAD+ products, such as a prescription face cream, target localized skin benefit rather than systemic energy metabolism, and are typically positioned for anti-aging use rather than a felt energy effect.

Across all four routes, biomarker changes typically show up within weeks of consistent use, while any subjective change, where it occurs at all, tends to be gradual and modest rather than immediate. Cost and convenience vary considerably: oral precursors are the easiest to start, while injectable and nasal prescription formats require a provider relationship and typically cost more per month.

Pro Tip: Ask any provider offering injectable or nasal NAD+ whether the compounding pharmacy documents sterility testing and endotoxin limits before you start treatment.

Safety and regulation: FDA guidance, compounding risks, and what to check

Because NAD+ is often delivered as a compounded injectable, sourcing and sterility matter as much as the ingredient itself. The FDA has issued reminders to compounders about using ingredients suitable for sterile compounding, after documenting cases where food-grade NAD+ was used to prepare sterile injectables. That practice creates contamination and endotoxin risks that would not exist with a properly graded pharmaceutical ingredient.

Compounding sterility and ingredient-grade issues have produced documented safety incidents; patients should verify that injectable products are made from sterile, pharmacopeial-grade ingredients and that the pharmacy documents sterility testing and endotoxin limits.

This caveat applies broadly, not only to NAD+. Reported adverse events tied to poorly compounded injectable products, including elevated endotoxin levels serious enough to trigger a recall, underscore why the pharmacy behind any injectable or nasal product matters as much as the molecule itself.

When evaluating any provider-supervised NAD+ option, a few quality signals are worth confirming before starting treatment:

  • The compounding pharmacy is licensed in the United States and subject to state and federal oversight.
  • The provider documents sterility and endotoxin testing for injectable or nasal products.
  • A licensed provider reviews your health history and supervises the treatment plan rather than leaving dosing to self-direction.

These same sourcing questions apply to other compounded injectables, including glutathione, where documented recalls have raised similar concerns about ingredient grade and contamination.

Our approach to NAD+ therapies at Vivo Clinic

We built our NAD+ offerings around the gap this evidence reveals: biomarkers respond more reliably than subjective fatigue, and sourcing quality affects both safety and outcomes. We specialize in provider-supervised anti-aging treatments using precision-compounded therapies such as NAD+ and Glutathione nasal sprays, injections, and creams, alongside Sermorelin, MIC+B12, Tirzepatide, and Semaglutide.

Every therapy we offer is precision-compounded by licensed U.S. pharmacies and delivered directly to patients, rather than sold as an unregulated over-the-counter product. We guide each patient through a personalized treatment selection process, paired with ongoing medical supervision and HIPAA-compliant handling of health data, so that decisions about dosing and format rest with a licensed provider rather than guesswork.

Our NAD+ nasal spray line reflects that structure directly: nasal spray, injection, and face cream formats, all prescription and compounded, built specifically around NAD+ delivery rather than treated as a side product.

What the evidence means for anyone considering NAD therapy

The research supports a narrower claim than most marketing implies: NAD+ precursors and therapies can reliably move biomarkers, but they do not reliably move how tired someone feels. Conventional wellness messaging tends to collapse that distinction, treating a biomarker increase as proof of an energy effect, when the 2024 trial and much of the 2022 review suggest otherwise.

What gets underweighted in most discussions is sourcing. Given that functional benefits are inconsistent at best, the sterility and quality of an injectable or nasal product become the more immediate safety variable, not a footnote. A patient weighing NAD therapy is better served asking about compounding standards and provider oversight than chasing a specific precursor name.

Anyone curious about NAD should prioritize a provider relationship over a product claim: a licensed provider who reviews health history, explains realistic expectations, and sources from an accountable compounding pharmacy addresses the real risk in this category, which is variability, not the biochemistry itself.

— Jack

If you want supervised NAD+ therapy, here’s how to start

Getting started with a provider-supervised NAD+ option follows a straightforward sequence: complete a telehealth intake, have a licensed provider review your health history and treatment goals, and, once approved, receive your prescription-compounded therapy from a licensed U.S. pharmacy shipped directly to your door. You can review the full process on our how it works page before starting.

For readers interested in a non-invasive format, our NAD+ nasal spray is priced at $129 per month, while our NAD+ face cream is also available at $129 per month for those focused on topical application. We do not promise a guaranteed energy outcome, since the evidence on subjective fatigue remains mixed, but every treatment plan includes licensed provider oversight from intake through refills.

This article is general information, not a substitute for advice from a licensed provider. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Does NAD+ give you energy?

NAD+ is required for the biochemical reactions that produce ATP, the molecule cells use as energy, but raising NAD+ levels does not reliably produce a felt increase in energy in human trials. A 2022 review found NAD+ precursors raised blood biomarkers while functional outcomes were mostly neutral.

Does NAD help with fatigue?

The evidence is mixed: a 2024 trial in long-COVID patients found no significant fatigue improvement from nicotinamide riboside, while a small pilot trial reported a short-term fatigue reduction. Results likely depend on dose, duration, and the specific population studied.

What should I check before choosing an NAD+ treatment?

Confirm that any injectable or nasal product comes from a licensed U.S. compounding pharmacy that documents sterility and endotoxin testing, since the FDA has warned about contamination risks tied to improperly sourced ingredients. A licensed provider should also review your health history before you start.

Is NAD+ similar to a stimulant like Adderall?

No. NAD+ is a coenzyme involved in cellular energy metabolism, not a central nervous system stimulant, and it works through a completely different biological pathway. Any perceived effect on alertness or energy is indirect and inconsistent across clinical trials, unlike the more immediate stimulant effect of prescription stimulant medications.

Sources